Dapagliflozin effects in patients with myocardial infarction

Dapagliflozin effects in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N44

Enrollment

100

Registered

2023-06-03

Start date

2023-06-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: The Intervention group will receive oral dapagliflozin of Modava pharmaceutical 10mg/day for 40 days in addition to usual treatments. Intervention 2: The Control group will receive o

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention Patients aged between 18 to 80 years Consented patients

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Renal failure (estimated glomerular filtration rate less than 30 ml/min) Hepatic failure Systolic blood pressure less than 100 mmHg Inflammatory and autoimmune diseases Diabetes mellitus Chronic heart failure Malignancy Psychiatric disorders Dapagliflozin contraindications History of receiving dapagliflozin History of myocardial infarction Arrival more than 6 hours from symptoms onset

Design outcomes

Primary

Measure	Time frame
ST-segment resolution. Timepoint: Before intervention and 90 min after intervention. Method of measurement: Electrocardiogram.;Cardiac troponin I. Timepoint: before intervention and then every 6 hours for the first 24 hours after intervention and every 12 hours to 72 hours after intervention. Method of measurement: ELISA test.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before the intervention and 3 days after the intervention. Method of measurement: Immunoturbidimetry method.;Cardiac ejection fraction. Timepoint: Before the intervention and 40 days after the intervention. Method of measurement: Echocardiography.;Major adverse cardiac events. Timepoint: Within 40 days after Intervention. Method of measurement: Interview.;Quality of life. Timepoint: Before the intervention and 40 days after the intervention. Method of measurement: MacNew questionaire.	—

Measure

Time frame

ST-segment resolution. Timepoint: Before intervention and 90 min after intervention. Method of measurement: Electrocardiogram.;Cardiac troponin I. Timepoint: before intervention and then every 6 hours for the first 24 hours after intervention and every 12 hours to 72 hours after intervention. Method of measurement: ELISA test.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before the intervention and 3 days after the intervention. Method of measurement: Immunoturbidimetry method.;Cardiac ejection fraction. Timepoint: Before the intervention and 40 days after the intervention. Method of measurement: Echocardiography.;Major adverse cardiac events. Timepoint: Within 40 days after Intervention. Method of measurement: Interview.;Quality of life. Timepoint: Before the intervention and 40 days after the intervention. Method of measurement: MacNew questionaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaher Entezari Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3335 5983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026